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ABSTRACT
Introduction: It is recommended that non-operative
treatment of knee osteoarthritis (KOA) should be
individually tailored and include multiple treatment
modalities. Despite these recommendations, no one
has yet investigated the efficacy of combining several
non-surgical treatment modalities in a randomised
controlled study. The purpose of this randomised
controlled study is to examine if an optimised,
combined non-surgical treatment programme results in
greater improvements in pain, function and quality of
life in comparison with usual care in patients with KOA
who are not eligible for total knee arthroplasty (TKA).
Methods and analysis: This study will include 100
consecutive patients from the North Denmark Region
not eligible for TKA with radiographic KOA (K-L grade
≥1) and mean pain during the previous week of
≤60 mm (0–100). The participants will be randomised
to receive either a 12-week non-surgical treatment
programme consisting of patient education, exercise,
diet, insoles, paracetamol and/or NSAIDs or usual care
(two information leaflets containing information on
KOA and advice regarding the above non-surgical
treatment). The primary outcome will be the change
from baseline to 12 months on the self-report
questionnaire Knee Injury and Osteoarthritis Outcome
Score (KOOS)4 defined as the average score for the
subscale scores for pain, symptoms, activities of daily
living and quality of life. Secondary outcomes include
the five individual KOOS subscale scores, pain on a
100 mm Visual Analogue Scale, EQ-5D, self-efficacy,
pain pressure thresholds, postural control and
isometric knee flexion and knee extension strength.
Ethics and dissemination: This study was approved
by the local Ethics Committee of The North Denmark
Region (N-20110085) and the protocol conforms to
the principles of the Declaration of Helsinki. Data
collection will be completed by April 2014.
Publications will be ready for submission in the
summer of 2014.
Trial registration number: This study is registered
with http://clinicaltrials.gov (NCT01535001).
INTRODUCTION
Knee osteoarthritis (KOA) is a prevalent degen-
erative disease that contributes to pain, reduced
functional level and poorer quality of life in
older adults.1–3 As a consequence, the burden
for the society, due to the cost of the interven-
tions and the persistent clinical course, is sub-
stantial.4–6 A prevalence of up to 40% in
women and 30% in men aged 65–75 years
ARTICLE SUMMARY
Article focus
▪ Does an optimised non-surgical treatment pro-
gramme result in greater improvements in pain,
function and quality of life in comparison with
written information on non-surgical treatment
options in knee osteoarthritis (KOA)?
Key messages
▪ The results of this study will provide evidence of
the efficacy of combining several non-surgical
treatment modalities for KOA.
▪ If the optimised non-surgical treatment pro-
gramme improves pain, function and quality of
life, it could highlight the importance of imple-
menting the recommendations in clinical
practice.
Strengths and limitations of this study
▪ The recruitment of participants and the multi-
modal approach resembles contemporary exam-
ination and treatment of KOA in Denmark and
several other countries.
▪ The semistructured nature of the MEDIC-treatment
enables individualisation of the treatment within
the possibilities of a randomised controlled trial
framework.
▪ The multimodal approach makes it impossible to
identify the efficacy of the different treatment
modalities alone.
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based on radiological diagnoses of KOA has been
reported,7 8 while approximately 30–33% of the
community-dwelling population older than 65 years have
symptomatic KOA.9 10 Given that the number of people
with symptomatic KOA has increased substantially during
the last 20 years11 and is expected to continue to increase,12
the need to reduce the size of the problem is obvious.
It is recommended that the treatment of KOA include
multiple treatment modalities,13 14 and that it should be
targeted on the basis of the characteristics of the individ-
ual.13 15 This is supported by a previous randomised con-
trolled trial (RCT) suggesting that there may be an
additive effect of exercise and weight loss.16
As a result of existing evidence, a combination of
patient education, exercise and weight loss are recom-
mended as the ﬁrst choice of treatment, with insoles
and medication as additional treatment modalities.13–15
Exercise16–20 and weight loss16 21 22 have been shown to
be effective in reducing pain and improving functional
level in patients with KOA. Furthermore, there is evi-
dence that patients with KOA undergoing patient educa-
tion experience reduced pain and functional disability
as well as improved well-being,19 23 24 while insoles have
been recommended as part of a multimodal treatment,
although the evidence concerning their efﬁcacy is con-
ﬂicting.14 25–27 Acetaminophen (paracetamol) is recom-
mended as the primary analgaesic13–15 as it reduces pain
in KOA,28 29 while short-term NSAIDs are recommended
when an addition of a second analgaesic is needed due
to insufﬁcient pain control.13 14 However, clinical prac-
tice does not always reﬂect the recommendations30–33
and usual care in patients not eligible for a total knee
arthroplasty is often only oral or written information on
KOA and advice regarding recommended treatments.
Despite the recommendations of an individualised, multi-
modal treatment approach, no one has yet investigated the
combined efﬁcacy of all the recommended non-surgical
treatment modalities in a controlled design. By combining
the recommended non-surgical treatment modalities, it
might be possible to optimise the treatment effect.
The purpose of this study is to examine whether a
12-week evidence-based non-surgical treatment pro-
gramme (the MEDIC-treatment) results in greater
improvement in quality of life, pain and function com-
pared to usual care (two information leaﬂets containing
information on KOA and advice regarding the recom-
mended treatments) in patients with KOA, who are not
eligible for a TKA and have no more than moderate pain.
We hypothesise that the optimised non-surgical treat-
ment will result in signiﬁcantly greater pain reduction,
functional improvement and increase in quality of life
than usual care at the 12-month follow-up.
METHODS AND ANALYSIS
Study design
This is a randomised, assessor-blinded, controlled trial of a
12-week multimodal, optimised non-surgical treatment
(the MEDIC-treatment) with 12-month follow-up.
Measurements will be taken at baseline, and after 12, 26
and 52 weeks. The study will conform to CONSORT guide-
lines for reporting parallel group randomised trials.34
Participants
Patients with a diagnosis of symptomatic and radio-
graphic KOA considered ineligible for TKA will be
included in this study.
We will recruit 100 patients meeting all of the follow-
ing inclusion criteria:
1. Referred from primary care to an orthopaedic
surgeon in a public hospital in The North Denmark
Region for evaluation of the need for TKA;
2. Considered ineligible for a TKA by the surgeon;
3. Diagnosed with KOA using standing, weight-bearing
knee radiographs (Kellgren-Lawrence score ≥1 on
the original scale35 36);
4. Aged ≥18 years;
5. KOOS4≤75 (the average score for four of the ﬁve
Knee Injury and Osteoarthritis Outcome Score sub-
scales covering pain, symptoms, activities of daily
living and quality of life).37 38
The exclusion criteria are any of the following:
1. Previous ipsilateral knee arthroplasty;
2. Rheumatoid arthritis;
3. Mean pain the previous week >60 mm on a 100 mm
Visual Analogue Scale (VAS);
4. Possible pregnancy or planning pregnancy;
5. Inability to comply with the protocol;
6. Inadequacy in written and spoken Danish.
Procedure
The overall structure of this study is outlined in ﬁgure 1.
People in need of evaluation for TKA in The North
Denmark Region are referred by their general practi-
tioner to an orthopaedic surgeon at the outpatient
clinics at Frederikshavn and Farsoe, Department of
Orthopaedic Surgery, who specialises in TKAs. A stan-
dardised weight-bearing anteroposterior knee x-ray is
obtained on arrival.8
The orthopaedic surgeon will assess potential partici-
pants against inclusion criteria 1–4 and exclusion cri-
teria 1–2 and a research health worker assigned to the
project will assess them against inclusion criterion 5 and
exclusion criteria 3–6. The research health worker will
obtain informed written consent from patients who are
eligible and willing to participate after they have
received written and verbal information. After the base-
line measures are obtained, patients who agree to par-
ticipate in the RCT will be assigned to one of two
treatments: (1) the MEDIC-treatment or (2) usual care.
Participants will be reassessed 3 months after random-
isation (12-week follow-up) and again after 6 months
(26 weeks) and 12 months (52 weeks). In addition, there
will be long-term follow-ups 2, 5 and 10 years after ran-
domisation. All current medication use, co-morbidities
and co-interventions will be recorded at all follow-ups.
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Patients declining to participate will be asked to ﬁll
out the Knee Injury and Osteoarthritis Outcome Score
(KOOS) and report age and gender anonymously so as
to improve the selection bias analysis.
Randomisation procedure and concealment of allocation
Before the initiation of the trial, the schedule for random-
isation will be randomly generated in permuted blocks
using a computer. To control for variation in patient char-
acteristics between the two clinics, the randomisation will
be stratiﬁed according to the clinic (Frederikshavn or
Farsoe). The allocation numbers will be put in concealed,
opaque C5 envelopes to conceal the outcomes of the ran-
domisation. In blocks of eight, these envelopes will be
placed in consecutively numbered opaque larger envel-
opes (seven larger envelopes in total for each clinic). A
staff member, independent of this study, will prepare the
envelopes. These will only be accessible by one research
assistant at each of the respective clinics. A smaller
envelope from the numbered larger envelopes will be
opened by the research assistant following the informed
consent and completion of the baseline measures, after
which the allocation will be revealed to the participant.
The smaller envelopes of the second larger envelope will
be added, when only two smaller envelopes are left in the
ﬁrst of the numbered larger envelopes. The last two of the
smaller envelopes will be added, when there are six
smaller envelopes left in the sixth of the seven numbered
larger envelopes at each clinic.
Blinding
The outcome assessor will be blinded to group alloca-
tion, unafﬁliated with the treatment sites and not
involved in providing the interventions. The partici-
pants, the project physiotherapist and the project diet-
ician delivering the interventions cannot be blinded.
The statistician performing the statistical analyses will be
blinded.
Figure 1 Flowchart.
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Interventions
MEDIC-treatment
The MEDIC-treatment consists of ﬁve different interven-
tions. Following the clinical guidelines, patient educa-
tion, exercise and weight loss are the three core
elements, while insoles and pharmacological treatment
will be included when meeting objective test criteria and
if considered needed by the treating clinician.13–15
Participants allocated to the MEDIC-treatment will
start the intervention right away. The MEDIC-treatment
will take place in Aalborg. Both the project physiother-
apist and the project dietician will be the same.
Patient education
The aim of the patient education is to help the partici-
pant to take responsibility for and actively engage in the
treatment and management of their disease. The patient
education consists of two sessions with a duration of
60 min each focusing on the diagnosis, the aetiology,
symptoms, risk factors and treatment of KOA. In add-
ition, the participants will receive a DVD containing the
information provided during the patient education.
Both sessions will be held by the project physiotherapist.
Exercise
The exercises will consist of the NEuroMuscular
EXercise training programme for patients with osteo-
arthritis of the knee or hip (NEMEX-TJR).39 The
NEMEX-TJR is based on neuromuscular principles and
has been found feasible in patients with hip or knee
OA.39 The exercise will be completed two times each
week during the 12-week intervention period. Each exer-
cise session will have a duration of 60 min.
After the intervention period the exercise will grad-
ually shift towards home-based individual exercise, since
the combination of class-based and individual home-
based exercise has been shown to reduce pain more
than home-based exercise alone.40
Diet
Participants with a body mass index (BMI)≥25 at base-
line will be referred to a dietician for a 12-week dietary
weight loss programme. The aim of the intervention is
to reduce the body weight by at least 5% and retain the
weight loss throughout the project period.22 Participants
referred to the weight loss programme will have four
dietary sessions.
Insoles
The participants will receive an individually ﬁtted full-
length Formthotics System insole with medial arch
support (Foot Science International, Christchurch,
New Zealand). Depending on hip-knee-foot alignment a
lateral wedge will be added to the insole. The project
physiotherapist will assess knee alignment using the
single limb mini squat previously found to be a valid and
reliable tool when investigating mediolateral motion of
the knee in clinical settings.41
Medicine
Paracetamol 1 g four times daily, ibuprofen 400 mg three
times daily and pantoprazol 20 mg daily will be pre-
scribed for use during the intervention period. The pre-
scription will be renewed every 3 weeks in order to
supervise the use of, and indications for, medication. The
participants will be instructed to contact the research
physiotherapist if they experience pain relief, which
make them question continuation of the prescription.
A more thorough description of the ﬁve elements of
the MEDIC-treatment and the delivery of it is published
in the study protocol for another study on KOA.42
Strategies to improve adherence
Following the intervention period, the participants will
be encouraged to continue the MEDIC-treatment at
home. To improve adherence there will be a transition
period of 8 weeks. During the transition period all parti-
cipants will alternate between class exercise home exer-
cises. Those enrolled in the weight loss programme will
be given two additional 30-min telephone sessions with
the project dietician. In addition, the project physiother-
apist will contact the participants by telephone eight
times in the period between the transition period and
the 12-month follow-up.16 43 44
Usual care
Participants allocated to usual care will be given two stan-
dardised information leaﬂets after the randomisation
(participants allocated to MEDIC-treatment will also be
given the information leaﬂets). The ﬁrst leaﬂet contains
general information on where in the North Denmark
Region it is possible to get help changing one’s lifestyle
and advice on how to do it. The second leaﬂet holds brief
information on what KOA is, symptoms of KOA and a
brief overview of the current treatment options as well as
some self-help tools related to KOA.
Discontinuation of allocated treatment
Participants experiencing worsening of symptoms will be
reassessed by the orthopaedic surgeon assessing them at
the inclusion stage. Pre-deﬁned criteria to be considered
eligible for TKA are a score for quality of life and/or for
pain equal to or below 25 on the KOOS and agreement
between the participant and the orthopaedic surgeon
that a TKA is necessary. The reason for each discontinu-
ation will be registered.
Baseline data
The radiographic severity of KOA will be assessed from the
baseline x-ray using the Kellgren and Lawrence grading
system.35 Furthermore, the following will be obtained by
questionnaire: gender, age, nationality, height, alcohol
intake, smoking habits, duration of KOA symptoms, previ-
ous injuries, treatment and use of medication regarding
the affected knee, co-morbidities, physical activity and
exercise levels, preferred treatment, previous arthroplas-
ties, living arrangement, satisfaction with self-management
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of pain, education level and employment status, income,
home help and the short version of the Hip/Knee
Osteoarthritis Decision Quality Instrument (HK-DQI).45
After the randomisation, the participants will be asked to
rate their belief in the effect of their received treatment
on pain, function and quality of life.
Primary outcome measure
The primary outcome will be the change from baseline
to 12 months in KOOS4, with scores ranging from 0
(worst) to 100 (best; table 1).
Secondary outcome measures
A number of other patient-reported outcome measures
will be taken (table 1): The ﬁve individual subscales of
KOOS (the ﬁfth scale being difﬁculty in sports and rec-
reational activities),37 38 the EQ-5D-3L,46 and pain inten-
sity measured on a 100 mm VAS with terminal
descriptors of ‘no pain’ and ‘worst pain possible’ in the
following situations: at rest, after 30 min. of walking, and
worst pain and least pain in the previous 24 h. The parti-
cipants will be asked to shade regions on a region-
divided body chart where they have had pain during the
previous 24 h. Furthermore, self-efﬁcacy in relation to
reduction in pain and increase in function and quality
of life using a 100 mm VAS with terminal descriptors of
‘very unsure’ and ‘very sure’ will be used in this study.
Several objective measures will be assessed (table 1).
The outcome assessor will be the same as in another trial
involving KOA with the same objective measure42—
someone who has undergone a period of supervised
training in the use of the objective measures to optimise
the reliability of the measurements. As measures of the
functional performance of the participants, the Timed
Up and Go47 and 20 mr walk test48 will be taken in this
study. In addition, percentage change in weight from
baseline to follow-up will be assessed. The measurement
of weight will be performed barefooted on the same
scales (seca 813, seca gmbh & co. kg., Hamburg,
Germany) and at the same time of day.
Maximum isometric muscle strength will be measured
in knee ﬂexion and knee extension bilaterally in a make
test using a handheld dynamometer (HHD), the
Powertrack II Commander ( JTech Medical Industries,
Salt Lake City, Utah, USA). The procedure of this object-
ive measure has been presented previously42 for both
knee extension and knee ﬂexion. The participant will
be given a 30 s rest between each measurement.
To assess pressure pain thresholds (PPTs), a hand-held
pressure algometer (Algometer Type II, Somedic AB,
Table 1 Study measures to be collected
Instrument for data collection Collection points
Primary outcome measure
KOOS4, average score of four of
the KOOS subscale scores
KOOS subscales pain, symptoms, ADL and QOL 0, 12, 26 and 52 weeks
Secondary outcome measures
Pain, symptoms, ADL, Sport &
Rec and QOL
KOOS 0, 12, 26 and 52 weeks
Health outcome EQ-5D-3L 0, 12, 26 and 52 weeks
Self-efficacy for improving pain,
function and QOL
100 mm VAS 0, 12, 26 and 52 weeks
Pain intensity in various situations 100 mm VAS 0, 12, 26 and 52 weeks
Pain location Paper-based pain mannequin 0, 12, 26 and 52 weeks
Functional performance Timed up and go 0, 12, 26 and 52 weeks
Functional performance 20 m walk test 0, 12, 26 and 52 weeks
Weight Scale (seca 813) 0, 12, 26 and 52 weeks
Maximum isometric knee muscle
strength in flexion and extension
Handheld dynamometer (Powertrack II Commander) 0, 12, 26 and 52 weeks
Pain reactions Handheld algometer (Algometer Type II)—pain pressure
thresholds at six sites (four sites in the peripatellar region,
m. tibialis anterior, m. extensor carpi radialis longus)
0, 12, 26 and 52 weeks
Postural balance Force platform (Metitur Good Balance) 0, 12, 26 and 52 weeks
Other measures
Compliance with exercise Treatment records, log-book Continuously
Use of medication Questionnaire 0, 12, 26 and 52 weeks
Compliance with diet, insoles and
patient education
A five-point Likert scale (ranging from ‘never’ to ‘all the
time’)
0, 12, 26 and 52 weeks
Satisfaction A five-point Likert scale (ranging from very dissatisfied to
very satisfied)
0, 12, 26 and 52 weeks
Adverse events Treatment records and questionnaire Continuously
Health and non-healthcare costs Questionnaire 0, 12, 26 and 52 weeks
ADL, activities of daily living; QOL, quality of life; Sport & Rec, sports and recreational activities.
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Hoerby, Sweden) with a 1 cm2 probe will be used. The
probe will be placed perpendicular to the skin and force
applied at a constant rate of 30 kPa/s until the partici-
pant deﬁnes the pressure as pain and presses a button.
PPTs will be assessed bilaterally at four sites in relation
to bony landmarks in the peripatellar region: (1) 3 cm
medial to the midpoint of the medial edge of the
patella, (2) 2 cm proximal to the superior edge of the
patella, (3) 3 cm lateral to the midpoint of the lateral
edge of the patella and (4) at the centre of the patella.
Furthermore, PPTs will be assessed at two control sites:
(5) one on m. tibialis anterior (5 cm distal to the tibial
tuberosity) and (6) one on m. extensor carpi radialis
longus (5 cm distal to the lateral epicondyle of the
humerus; ﬁgure 2). Before starting the measurement,
the test is performed once or more on the dorsal
aspects of the hand to make sure that the participant
has understood the test procedure. A PPT will be
obtained twice from each site and the mean of the two
measurements will be used in the statistical analysis.49 50
The participant will be asked about the location and
type of their knee pain using the interviewer-
administered questionnaire Knee Pain Map, which has
been found to be reliable for this purpose.51
The test setup for both isometric muscle strength and
PPTs will be investigated in a test–retest reliability study
on 20 participants.
Postural balance will be assessed using an instrumented
force platform (Good Balance, Metitur Oy, Jyvaskyla,
Finland), measuring the centre of pressure (COP) excur-
sion body sway of the participants (100Hz). Participants
will be asked to stand barefooted in a comfortable position
with their feet positioned side-by-side (about a shoulder
width apart). Further, they will be given the standardised
cue ‘Stand as still as possible’ with their arms folded across
their chest while focusing their eyes on a visual target posi-
tioned 3 m away while being tested. Four different sensory
conditions will be applied to explore the contribution of
different conditions to the postural control in these
patients: (1) standing on a ﬁrm surface with eyes open, (2)
standing on a ﬁrm surface with eyes closed, (3) standing
on a soft surface (foam) with eyes open and (4) standing
on a soft surface (foam) with eyes closed. Each condition
will last 1 min and be repeated three times in a random
order. During all measurements, an experienced experi-
menter will be standing next to the patient in case they
lose their balance. Between each trial, participants will
have the option of a rest if needed. Bipedal static COP
measures have previously been proven to be a reliable tool
for investigating postural balance.52
Other measures
A number of other measures will be obtained in this study
(table 1). In the group allocated to MEDIC-treatment,
compliance with exercise will be monitored by the physio-
therapist during the intervention period as the total
number of exercise sessions completed out of the planned
24 sessions (2 sessions a week for 12 weeks). Good compli-
ance is deﬁned as participation in 75% or more of the
exercise sessions, medium compliance as participation in
50–74% of the sessions and poor compliance as participa-
tion in less than 50% of the sessions. The participants in
the group allocated to the MEDIC-treatment will be
requested to record their weekly exercise until the long-
term follow-up 2 years after randomisation to investigate
the long-term compliance. Use of medication in the group
allocated to the MEDIC-treatment will be recorded in a
medication diary, which will be examined as part of the
follow-up. At each follow-up, all participants will be asked
to report their compliance with what they have learned in
this study using a ﬁve-point scale (never, every month,
every week, everyday, all the time). All participants will also
be asked to rate their satisfaction with the treatment to
date on a ﬁve-point Likert scale at each follow-up.
Adverse and seriously adverse events will be registered in
two ways and divided into index knee or sites other than
index knee. The project physiotherapist will record any
adverse events that the participant experiences or tells them
about. At all follow-ups, the assessor will use open-probe
questioning to assess adverse events in all participants.
Information on direct healthcare costs and direct non-
healthcare costs will be collected retrospectively and at allFigure 2 Pressure pain thresholds measurement sites.
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follow-ups. Direct healthcare costs will include cost of the
MEDIC-treatment and compliance with the treatment.
These elements will be valued using published Danish
prices for medical costs. Direct non-healthcare costs will
include sick pay (if relevant), change in home help,
number of days lost from work and shorter working hours.
Sample size
It is expected that the group allocated to MEDIC-treatment
will improve 10 points more than the group allocated to
usual care based on the primary outcome KOOS4 at the
main endpoint after 12 months. With a common between-
subject SD of 14, sample size calculations show that 41 parti-
cipants in each group are required to detect a statistical dif-
ference (power of 90% and signiﬁcance level at 0.05
(two-sided)). Therefore, a total of 100 participants will be
included to allow for crossovers and missing data (drop-out
rate will be set to 20%). The minimal clinically important
difference between patients having optimised non-surgical
treatment in patients not considered eligible for TKR is not
known. Some studies have applied an improvement of 15%
as a cut-off to determine number needed to treat (NNT).53
We will closely follow the ongoing discussion within this
area and apply a cut-off supported by current knowledge at
the time of analysis.
Statistical analysis
The primary outcome measure will be the KOOS4 score
at the 12-month follow-up. The statistical analysis will
follow an intention-to-treat approach and be based on a
Generalised Estimating Equations regression model for
the KOOS4 score at all follow-ups to take the repeated
measurements on the patients into account. The follow-
ing aspects will be incorporated in the model: the effects
of treatment, follow-up time, treatment-by-follow-up time
interaction, and KOOS4 score at baseline. Secondary ana-
lyses will assess heterogeneity between sites and a
within-group analysis will be done to investigate if treat-
ment compliance is associated with the change in
KOOS4. Furthermore, an analysis of NNT will be per-
formed. NNTestimates the number of people who would
need to go through the MEDIC-treatment for one person
to have a clinically meaningful improvement in KOOS4
from baseline to the follow-ups.
ETHICS AND DISSEMINATION
Ethical considerations
The protocol is designed to conform to the principles of
the Declaration of Helsinki and has been approved by the
local Ethics Committee of The North Denmark Region
(N-20110085). The participants in this study will be allo-
cated to either usual care or the MEDIC-treatment, which
means that the treatment they receive will be either equiva-
lent to, or superior to, the treatment that they would
receive if they did not participate in this study.
Timelines and dissemination plans
Approval from The Danish Data Protection Agency was
given in January 2012 while ethics approval was obtained
from The North Denmark Region in February 2012.
Recruitment and training of the involved project physio-
therapist and dietician were undertaken in July and
August 2011 and recruitment of participants started in
April 2012.
All participants are expected to have completed the
12-month follow-up by April 2014. The statistical analysis
will start immediately after the data monitoring is com-
pleted. Publications will be ready for submission in the
summer of 2014.
CONCLUSIONS
The lack of evidence regarding the efﬁcacy of the cur-
rently recommended multimodal non-surgical treatment
approach to knee osteoarthritis (KOA) indicates a strong
need for thoroughly designed clinical trials. Therefore, we
have designed this study as a randomised controlled trial
to investigate if a 12-week optimised, multimodal non-
surgical treatment is more efﬁcacious than written infor-
mation on non-surgical treatment options in patients with
KOA not eligible for a total knee arthroplasty. Since it is
the ﬁrst study combining these recommended treatments
in a randomised controlled study, the results will provide
evidence about the efﬁcacy of the combination of non-
surgical treatment modalities for KOA.
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